|
|
Post by pguererro on Jun 17, 2021 22:32:38 GMT -5
I will continue to comment Real World Facts in the Endo Industry as long as there are terribly uninformed comments on this board about Afrezza. MannKind might still be a good investment and MNKD might flourish some day, but it won’t be because of Afrezza. I can’t listen to the uninformed comments on why Afrezza hasn’t made it. I’ve addressed all those excuses for 2 plus years now and only get smart ass responses. I’ve been correct the entire time on Afrezza. The numbers don’t lie. Stop making uninformed excuses about this drug. I’ve been correct on the growth/future/scripts/dollar revenue on this drug for over 2 years now. Proceed with snarky comments but accept reality.
|
|
|
|
Post by pguererro on Jun 17, 2021 22:42:16 GMT -5
I’ll stop giving you real world reality when I stop reading the same ridiculous, false reasons why Afrezza hasn’t made it. Btw EVERY endo in the country has heard of Afrezza. 4 Billion dollars has been spent on this drug.
|
|
|
|
Post by pguererro on Jun 17, 2021 22:57:22 GMT -5
For the record, my closest fellow MNKD rep/confidant who taught me more about diabetes than spending 6 yrs with novo nordisk and praises Afrezza to this day (of course she left because as I have said nothing is sustainable selling Afrezza) still went to the ER twice in 2 yrs with dangerous lows. Still loves Afrezza and is taking it after leaving. So the “less hospitalizations” theory probably doesn’t work either. More real world feedback.
|
|
|
|
Post by porkini on Jun 17, 2021 23:28:40 GMT -5
I’ll stop giving you real world reality when I stop reading the same ridiculous, false reasons why Afrezza hasn’t made it. Btw EVERY endo in the country has heard of Afrezza. 4 Billion dollars has been spent on this drug. BULLSHIT, plain and simple! |
|
|
|
Post by itellthefuture777 on Jun 18, 2021 4:01:45 GMT -5
|
|
|
|
Post by cretin11 on Jun 18, 2021 5:54:55 GMT -5
I’ll stop giving you real world reality when I stop reading the same ridiculous, false reasons why Afrezza hasn’t made it. Btw EVERY endo in the country has heard of Afrezza. 4 Billion dollars has been spent on this drug. BULLSHIT, plain and simple! It’s interesting that peppy, you accused pguererro of sounding angry in his posts. However, pguererro’s posts seem straightforward and not overly emotional, rather they simply present his experiences in the world of selling Afrezza. The message he conveys is not one you want to hear, so perhaps you interpret him as angry for some reason? Moreover, lots of responses to pguererro seem more emotional that his own posts. Take the exchange above, there are two posters. One of them does seem angry, but it’s not pguererro is it? Thank you peppy for all the great info you take time to share on the Volume threads. Likewise, we should appreciate getting to read the perspective of pguererro who, unlike the rest of us, has spent real world time and energy trying to sell the drug we all believe so much in. |
|
|
|
Post by mcbone on Jun 18, 2021 6:51:50 GMT -5
The statement was BS. There are still endos who have not heard of Afrezza. Pguererro's posts IMO smack of a salesperson who failed to sell Afrezza, got fired or quit, and now has an extremely negative attitude about the product. Happens all the time in sales.
|
|
|
|
Post by cretin11 on Jun 18, 2021 7:10:32 GMT -5
The statement was BS. There are still endos who have not heard of Afrezza. Pguererro's posts IMO smack of a salesperson who failed to sell Afrezza, got fired or quit, and now has an extremely negative attitude about the product. Happens all the time in sales. This is another example of someone making assumptions about pguererro apparently because you don’t like his perspective. Sports has said the opposite of what you (and others) are saying, I’ll choose to trust her knowledge. |
|
|
|
Post by uvula on Jun 18, 2021 7:37:02 GMT -5
One thing that sounds obviously true is that it is difficult to make a lot of money being an afrezza sales rep. The ratio of scripts per rep is rather small. I wonder how many reps are employed for more than 1 year.
|
|
|
|
Post by centralcoastinvestor on Jun 18, 2021 8:04:19 GMT -5
Somehow this thread got hijacked into complaining about poor Afrezza sales. I believe there are other threads for that. So lets get back on the topic of this thread.
We need to celebrate the incredible news that the FDA has accepted an accelerated approval process for Tyvaso DPI. What is really amazing to me, is that everyone including myself thought that the earliest date we could receive FDA approval was December but it turns out it is October. Two months faster than all of us thought. So lets think about that for a minute. We are just 4 months away from a likely approval of another Technosphere product that is being marketed by the very talented company United Therapeutics. We should begin seeing royalty payments by the end of 2021. This sets up 2022 as the likely year that MannKind becomes profitable. So regardless of what the negative nellies say, MannKind is in the very best growth and financial position they have ever been in. It is something to celebrate.
|
|
|
|
Post by neil36 on Jun 18, 2021 9:03:20 GMT -5
Somehow this thread got hijacked into complaining about poor Afrezza sales. I believe there are other threads for that. So lets get back on the topic of this thread. We need to celebrate the incredible news that the FDA has accepted an accelerated approval process for Tyvaso DPI. What is really amazing to me, is that everyone including myself thought that the earliest date we could receive FDA approval was December but it turns out it is October. Two months faster than all of us thought. So lets think about that for a minute. We are just 4 months away from a likely approval of another Technosphere product that is being marketed by the very talented company United Therapeutics. We should begin seeing royalty payments by the end of 2021. This sets up 2022 as the likely year that MannKind becomes profitable. So regardless of what the negative nellies say, MannKind is in the very best growth and financial position they have ever been in. It is something to celebrate. Thanks for the nudge back on topic. I inadvertently opened the door to thread drift by rhetorically asking when Tyvaso DPI sales would become the leading source of revenue to the company. I should have asked (rhetorically) how much money is Mannkind currently losing each quarter and how soon could Tyvaso DPI sales realistically close that gap. Appreciate you getting us back on topic. The FDA acceptance and potential October approval date is incredibly good news. |
|
|
|
Post by oldfishtowner on Jun 18, 2021 9:27:52 GMT -5
Maybe, maybe not. I would like to see MNKD's participation in the Medicare Part D Senior Savings Model surprise everyone and double or triple scripts in 2022. But this probably requires that MNKD has to have a robust marketing program targeted to this segment, like ads in AARP's magazine, TV commercials targeted to seniors with Medicare Part-D, sales reps making sure that prescribers know that MNKD is participating in the program and what the cost is to patients, and maybe pamphlets distributed in physicians offices. Spending all that marketing money could be money down the drain if the Medicare Part D plans don't include Afrezza in their formularies. As it stands, almost none of them do. And since the PR release about the Senior Savings program I haven't heard Mike mention it at any of his public appearances. "Under the Model, which began on January 1, 2021, CMS is testing a change where Part D sponsors that participate in the Model offer beneficiaries prescription drug plans that provide supplemental benefits for a broad range of insulins [my underline] in the coverage gap phase of the Part D benefit."
"Part D sponsors participating in the Model will offer beneficiaries plan choices that provide broad access to multiple types of insulin [my underline], marketed by Model-participating pharmaceutical manufacturers, at a maximum copay of $35 each for a month’s supply in the deductible, initial coverage, and coverage gap phases of the Part D benefit." innovation.cms.gov/innovation-models/part-d-savings-model
It seems to me that if none of the sponsors who participate in the Model include Afrezza in their plans then the purpose of the Model is not being served and Mannkind, CMS and patients would have reason to complain. This is particularly so since Afrezza is the only inhaled insulin on the market and the only real ultra-rapid acting insulin. So I am assuming that MNKD will first of all be negotiating with sponsors to include Afrezza in their Medicare Part D and Medicare Advantage plans that participate in the Model, if that is necessary, and once Afrezza is included in those plans, launch a well thought out marketing effort targeted to seniors.
Also, it appears to me from the following statement on the same web page that Advantage plans with Part D benefits can participate in the Model.
"The Model aims to reduce Medicare expenditures while preserving or enhancing quality of care for beneficiaries, and offers additional Part D plan choices to beneficiaries who receive Part D coverage through standalone Prescription Drug plans (PDPs) or those who receive Part D coverage through Medicare Advantage [my underline], Prescription Drug plans (MA-PDs)."
|
|
|
|
Post by backwash on Jun 18, 2021 10:11:07 GMT -5
I appreciate your input. I'm long the stock and welcome both positive and negative input. Understanding the potential downside and risks associated with any investment is prudent. The gang on this msg board has always been ruthless towards anyone that posts anything negative about the company. For me, receiving info from people on the ground trying to sell the stuff or who have worked for the company is good stuff. Thanks again for sharing.
|
|
|
|
Post by peppy on Jun 18, 2021 10:18:03 GMT -5
Spending all that marketing money could be money down the drain if the Medicare Part D plans don't include Afrezza in their formularies. As it stands, almost none of them do. And since the PR release about the Senior Savings program I haven't heard Mike mention it at any of his public appearances. "Under the Model, which began on January 1, 2021, CMS is testing a change where Part D sponsors that participate in the Model offer beneficiaries prescription drug plans that provide supplemental benefits for a broad range of insulins [my underline] in the coverage gap phase of the Part D benefit."
"Part D sponsors participating in the Model will offer beneficiaries plan choices that provide broad access to multiple types of insulin [my underline], marketed by Model-participating pharmaceutical manufacturers, at a maximum copay of $35 each for a month’s supply in the deductible, initial coverage, and coverage gap phases of the Part D benefit." innovation.cms.gov/innovation-models/part-d-savings-model
It seems to me that if none of the sponsors who participate in the Model include Afrezza in their plans then the purpose of the Model is not being served and Mannkind, CMS and patients would have reason to complain. This is particularly so since Afrezza is the only inhaled insulin on the market and the only real ultra-rapid acting insulin. So I am assuming that MNKD will first of all be negotiating with sponsors to include Afrezza in their Medicare Part D and Medicare Advantage plans that participate in the Model, if that is necessary, and once Afrezza is included in those plans, launch a well thought out marketing effort targeted to seniors.
Also, it appears to me from the following statement on the same web page that Advantage plans with Part D benefits can participate in the Model.
"The Model aims to reduce Medicare expenditures while preserving or enhancing quality of care for beneficiaries, and offers additional Part D plan choices to beneficiaries who receive Part D coverage through standalone Prescription Drug plans (PDPs) or those who receive Part D coverage through Medicare Advantage [my underline], Prescription Drug plans (MA-PDs)."
My understanding, Heard in a video, By law Medicare is the only agency in the USA allowed to negotiate the price of drugs with the manufactures. (The rebate system, the private insurers are negotiating sale goals with rebates attached.) |
|
|
|
Post by sportsrancho on Jun 18, 2021 10:34:04 GMT -5
The statement was BS. There are still endos who have not heard of Afrezza. Pguererro's posts IMO smack of a salesperson who failed to sell Afrezza, got fired or quit, and now has an extremely negative attitude about the product. Happens all the time in sales. They don’t understand Afrezza let’s put it that way. I posted where a patient’s Endo told her it was only for type2. |
|
